Dr. Ram Manohar Lohia Hospital, a central government healthcare facility, has initiated an urgent recall of 10 batches of critical medications across its clinical departments and wards. The corrective measure was triggered after hospital quality assessments revealed that several formulations failed analytical standards or suffered from severe physical degradation. Hospital inventory management authorities acted swiftly to halt the administration of these compromised supplies, directing healthcare personnel to immediately return all remaining stock to central distribution units to safeguard patient health.
Four Official Recall Notices Issued Over Seven Days
The corrective measures unfolded through a sequence of four formal notifications circulated between September 7 and September 14. Hospital administrative circulars instructed every clinical department, outpatient desk, and inpatient ward to suspend the dispensing of the affected consignments without delay. Medical staff were asked to report any unusual patient observations, though clinical surveillance confirmed that no adverse medical episodes or critical side effects were documented among patients treated during the period.
Three Oral Formulations Declared Substandard
A notification issued on September 14 by the oral and topical drug unit confirmed that three separate tablet formulations were categorized as not of standard quality following analytical laboratory assessments. The substandard oral medications included sodium valproate 200 mg, an essential anti-epileptic therapy, alongside spironolactone 50 mg, prescribed for congestive heart failure and fluid retention. The third failed oral batch was imipramine 25 mg, an antidepressant commonly utilized in psychiatric and neurological clinical care.
Five Injectable Drugs Pulled from Clinical Use
Simultaneously on September 14, the hospital injectable drug division ordered the immediate withdrawal of five intravenous and intramuscular drug batches. Testing identified non-conformity in batches of adenosine, utilized in cardiac emergencies, and methylergometrine, a crucial medication administered to mothers to control postpartum bleeding following childbirth. The recall list for injectables also encompassed batches of pheniramine maleate, multi-vitamin injection, and ascorbic acid, prompting their comprehensive removal from hospital supply lines.
Physical Crumbling and Powder Formation in Tablet Strips
Physical inspections exposed severe manufacturing irregularities in two cardiac tablet lines. On September 9, a formal notice flagged that isosorbide mononitrate 20 mg tablets had degraded into loose powder inside their blister packaging. Manufactured by Glosun India Labs Private Limited in July 2026 with an expiration date of June 2028, departments were instructed to clear and return the stock within three days. A comparable defect was recorded on September 7 regarding metoprolol 50 mg tablets from Glosun India Labs, with additional supplies originating from Jackson Laboratories Private Limited.
Alternative Medications and Patient Safety Safeguards
Hospital leadership stated that standard clinical protocols were activated the moment testing confirmed the non-compliant results. To ensure uninterrupted medical treatment for all admitted individuals and outpatient visitors, hospital pharmacies arranged verified alternative formulations across all affected categories. Officials emphasized that rigorous monitoring protocols remain active, ensuring patient safety while maintaining zero disruption to ongoing critical healthcare services.
